New combo pill could offer safer cholesterol control for seniors

NCT ID NCT07626840

Not yet recruiting Disease control Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a moderate statin (pitavastatin) combined with ezetimibe against high-intensity statins (atorvastatin or rosuvastatin) in patients aged 75+ with coronary artery disease who need a stent. The goal is to see if the combo is just as good at preventing heart attacks, strokes, and other major events, but with fewer side effects like muscle pain or diabetes risk. 5,000 participants will be followed after their procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pitavastatin and ezetimibe combination (Livalozet 4/10mg)
What this could lead to: If successful, this could offer older heart patients a safer, equally effective cholesterol-lowering option with fewer side effects than high-intensity statins.
What could go wrong: This trial hasn't started yet and is large (5,000 participants), but it's testing non-inferiority, meaning the combo might not be better—just as good. Side effects like muscle pain or liver issues are still possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME (ACS) UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE CORONARY SYNDROME (ACS) UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) CORONARY ARTERY DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.